New drug zanzalintinib tested for advanced liver cancer

NCT ID NCT07042919

Recruiting now Disease control Sponsor: Devalingam Mahalingam Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called zanzalintinib in people with advanced liver cancer that has spread or cannot be cured. The trial has two parts: first, finding the safest dose, then checking if it helps control the cancer. About 59 participants will take the drug by mouth, and researchers will monitor side effects and tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanzalintinib
What this could lead to: If successful, this could provide a new treatment option for people with advanced liver cancer who have not responded to other therapies.
What could go wrong: This is an early-phase trial with only 59 participants, so results may not apply to everyone. Side effects from zanzalintinib are possible, and the drug may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA CIRRHOSIS STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Northwestern University
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.